

NB Drug Plans Biosimilar Initiative Reminder

The Biosimilars Initiative, announced in the NB Drug Plans Formulary Update - Bulletin #1050, involves switching patients who use certain originator biologics to a biosimilar brand to maintain their coverage under the New Brunswick Drug Plans.

As a reminder, **coverage of the originator biologics listed in the table below will end on November 30, 2021** or on the last day of the current special authorization approval, whichever is sooner.

Patients who are using one of these originator biologics will need to switch to the biosimilar brand to avoid disruption in their coverage.

Drug	Originator (Switch from)	Biosimilar (Switch to)
Adalimumab	Humira	Idacio Amgevita Hadlima Hyrimoz Hulio
Etanercept	Enbrel	Brenzys Erelzi
Infliximab	Remicade	Inflectra Renflexis Avsola
Insulin glargine	Lantus	Basaglar
Insulin lispro	Humalog	Admelog
Rituximab	Rituxan	Ruxience Truxima Riximyo
Glatiramer	Copaxone	Glatect

More information and resources, including the Biosimilars Initiative Guide for Prescribers and Health Professionals and Guide for Patients, are available online at www.qnb.ca/biosimilars.